Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial (NCT07526545) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
United States800 participantsStarted 2026-09-01
Plain-language summary
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Who can participate
Age range
50 Years – 75 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Males aged 50-75
* PSA 3-20 ng/ml within the previous 3 months
* Fit to undergo all procedures listed in protocol per treating physician's discretion
* No prostate biopsy in the past 4 years
* No prostate MRI in the past 2 years
* Able to provide written informed consent
Exclusion Criteria:
* Prior diagnosis of prostate cancer
* Contraindication to MRI (e.g. claustrophobia, pacemaker)
* Contraindication to prostate biopsy
* Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Clinically significant prostate cancer (csPCa), defined as Gleason Grade (GG) Group 2-5